(Q38418103)

2 September 2017

title

A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer (English)

1 reference

2 September 2017

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25867018%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Claire de Oliveira

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25867018%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Geoffrey Liu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25867018%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Jeffrey S. Hoch

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25867018%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Donna M Graham

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25867018%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Wanrudee Isaranuwatchai

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25867018%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Lillian L Siu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25867018%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

language of work or name

English

0 references

publication date

13 April 2015

1 reference

2 September 2017

number of pages

8

1 reference

inferred from page(s)

published in

Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25867018%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

121

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25867018%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25867018%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

1785-1792

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25867018%20AND%20SRC:MED&resulttype=core&format=json

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

9 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Introduction of human papillomavirus vaccination in Nordic countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

HPV vaccine against anal HPV infection and anal intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Head and neck cancer in Canada: trends 1992 to 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Trends in the incidence rates of tonsil and base of tongue cancer in England, 1985-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Trends in head and neck cancer incidence in Japan during 1965-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Impact of vaccinating boys and men against HPV in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

The cost-effectiveness of male HPV vaccination in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a Comprehensive Cancer Centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Prevalence of oral HPV infection in the United States, 2009-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Cost-effectiveness of intensity-modulated radiotherapy in oropharyngeal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

First-year quality of life assessment of an intra-arterial (RADPLAT) versus intravenous chemoradiation phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Quality of life after surgical treatment for oral and oropharyngeal cancer: a prospective longitudinal assessment of patients reconstructed by a microvascular flap

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Updating the natural history of human papillomavirus and anogenital cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

The epidemiology of oral HPV infection among a multinational sample of healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Human papillomavirus and survival of patients with oropharyngeal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Quality of life and head and neck cancer: a 5 year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Employment and return to work in head and neck cancer survivors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, Medicare, and Medicaid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Case-control study of human papillomavirus and oropharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

Seroprevalence and Determinants of Eight High-Risk Human Papillomavirus Types in Homosexual Men, Heterosexual Men, and Women: A Population-Based Study in Amsterdam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

7 January 2021

Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

7 January 2021

Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

7 January 2021

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29111

7 January 2021

Identifiers

DOI

10.1002/CNCR.29111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25867018%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference